Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Dow
AstraZeneca
Colorcon
Johnson and Johnson

Last Updated: December 7, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR MONOMETHYL FUMARATE

➤ Subscribe for complete access

« Back to Dashboard

All Clinical Trials for monomethyl fumarate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00837785 ↗ A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With MS Completed Biogen Phase 1 2009-02-28 To establish a pharmacokinetic (PK) profile of BG00012, as measured by its primary metabolite, monomethyl fumarate (MMF), during a 24-hour dosing period in subjects with relapsing-remitting multiple sclerosis (RRMS), with a variety of baseline demographic characteristics.
NCT01924832 ↗ BG00012 Regional Absorption Study Completed Biogen Phase 1 2013-08-01 The primary objective of this study is to evaluate the pharmacokinetics (PK) profile of monomethyl fumarate (MMF) following delivery of BG00012 (dimethyl fumarate, DMF) 120 mg (Part 1) and BG00012 240 mg (Part 2) to varying regions within the GI tract in healthy volunteers. The secondary objective of this study is to evaluate the safety and tolerability profile following the delivery of BG00012 120 mg (Part 1) and BG00012 240 mg (Part 2) to varying regions within the GI tract in healthy volunteers.
NCT02201849 ↗ A Study of ALKS 8700, a Monomethyl Fumarate (MMF) Molecule, in Healthy Adults Completed Alkermes, Inc. Phase 1 2014-07-01 This study will evaluate the safety, tolerability, and pharmacokinetics of ALKS 8700, a monomethyl fumerate (MMF) molecule.
NCT02201849 ↗ A Study of ALKS 8700, a Monomethyl Fumarate (MMF) Molecule, in Healthy Adults Completed Biogen Phase 1 2014-07-01 This study will evaluate the safety, tolerability, and pharmacokinetics of ALKS 8700, a monomethyl fumerate (MMF) molecule.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for monomethyl fumarate

Condition Name

Condition Name for monomethyl fumarate
Intervention Trials
Multiple Sclerosis 3
Relapsing Remitting Multiple Sclerosis 2
Relapsing Forms of Multiple Sclerosis 1
Healthy 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for monomethyl fumarate
Intervention Trials
Multiple Sclerosis 6
Sclerosis 3
Multiple Sclerosis, Relapsing-Remitting 2
Psoriasis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for monomethyl fumarate

Trials by Country

Trials by Country for monomethyl fumarate
Location Trials
United Kingdom 3
United States 3
Germany 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for monomethyl fumarate
Location Trials
Missouri 1
New York 1
Texas 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for monomethyl fumarate

Clinical Trial Phase

Clinical Trial Phase for monomethyl fumarate
Clinical Trial Phase Trials
Phase 4 1
Phase 3 1
Phase 1 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for monomethyl fumarate
Clinical Trial Phase Trials
Completed 7
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for monomethyl fumarate

Sponsor Name

Sponsor Name for monomethyl fumarate
Sponsor Trials
Biogen 5
Banner Life Sciences LLC 2
Alkermes, Inc. 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for monomethyl fumarate
Sponsor Trials
Industry 9
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Dow
Boehringer Ingelheim
Express Scripts
Medtronic
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.